Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory adalimumab biomarker study in moderate-to-severe hidradenitis suppurativa
2017-000435-13Phase 4Completed
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in hidradenitis suppurativa (HS), sponsored by Universitätsklinikum Frankfurt. Primary endpoint: Inflammatory cytokine pattern before TNF-alpha antagonist treatment. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2017-000435-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000435-13.